{
    "8JM.F": {
        "short_name": "VETOQUINOL INH.  EO 2,50",
        "long_name": "Vetoquinol SA",
        "summary": "Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of pain management, anti-infective, cardiology-nephrology, care and hygiene, antiparasiticides, behavior, internal medicine, and reproduction for cats, dogs, cattle, and pigs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "state": null,
        "city": "Lure",
        "zipcode": "70204",
        "website": "http://www.vetoquinol.com",
        "full_time_employees": 2409
    },
    "A8D.F": {
        "short_name": "AB SCIENCE S.A.  EO-,01",
        "long_name": "AB Science S.A.",
        "summary": "AB Science S.A., a clinical-stage pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases. The company is also developing AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase II clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "state": null,
        "city": "Paris",
        "zipcode": "75008",
        "website": "http://www.ab-science.com",
        "full_time_employees": null
    },
    "AB.PA": {
        "short_name": "AB SCIENCE",
        "long_name": "AB Science S.A.",
        "summary": "AB Science S.A., a clinical-stage pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases. The company is also developing AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase II clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "state": null,
        "city": "Paris",
        "zipcode": "75008",
        "website": "http://www.ab-science.com",
        "full_time_employees": null
    },
    "ABSCF": {
        "short_name": "AB SCIENCE",
        "long_name": "AB Science S.A.",
        "summary": "AB Science S.A., a clinical-stage pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases. The company is also developing AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase II clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "state": null,
        "city": "Paris",
        "zipcode": "75008",
        "website": "http://www.ab-science.com",
        "full_time_employees": null
    },
    "BOI.PA": {
        "short_name": "BOIRON",
        "long_name": "Boiron SA",
        "summary": "Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat flu like symptoms, such as fever, chills, headaches, and muscle aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and S\u00c3\u00a9datif PC to treat anxiety and emotional, and minor sleep disorders. The company's branded homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Hom\u00c3\u00a9optic to treat eye discomfort and irritation due to various causes for adults and children; Hom\u00c3\u00a9ovox for vocal disorders; and Arnigel Roll-on for the treatment of benign trauma in the absence of open wounds. In addition, it provides dietary supplement; Dermoplasmine, a lip balm stick; Reformulation of the Hom\u00c3\u00a9odent; Mag' Nuit, a dietary supplement; Osmobiotic to protect from gastric acid; Boc\u00c3\u00a9al, a throat spray homeopathic medicine for moderate sore throats with no fever, mouth sores, and small mouth lesions; Cocyntal to treat colic in infants and newborns; and hand sanitizer products, as well as physiological serum used to clean children's and babies' eyes and noses. The company offers its products through distribution centers, pharmacy chains, wholesalers, drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "state": null,
        "city": "Messimy",
        "zipcode": "69510",
        "website": "http://www.boiron.fr",
        "full_time_employees": 2842
    },
    "BON.F": {
        "short_name": "BOIRON SA INH.  EO 1",
        "long_name": "Boiron SA",
        "summary": "Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat flu like symptoms, such as fever, chills, headaches, and muscle aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and S\u00c3\u00a9datif PC to treat anxiety and emotional, and minor sleep disorders. The company's branded homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Hom\u00c3\u00a9optic to treat eye discomfort and irritation due to various causes for adults and children; Hom\u00c3\u00a9ovox for vocal disorders; and Arnigel Roll-on for the treatment of benign trauma in the absence of open wounds. In addition, it provides dietary supplement; Dermoplasmine, a lip balm stick; Reformulation of the Hom\u00c3\u00a9odent; Mag' Nuit, a dietary supplement; Osmobiotic to protect from gastric acid; Boc\u00c3\u00a9al, a throat spray homeopathic medicine for moderate sore throats with no fever, mouth sores, and small mouth lesions; Cocyntal to treat colic in infants and newborns; and hand sanitizer products, as well as physiological serum used to clean children's and babies' eyes and noses. The company offers its products through distribution centers, pharmacy chains, wholesalers, drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "state": null,
        "city": "Messimy",
        "zipcode": "69510",
        "website": "http://www.boiron.fr",
        "full_time_employees": 2842
    },
    "I7G.F": {
        "short_name": "IPSEN S.A. PORT.  EO 1",
        "long_name": "Ipsen S.A.",
        "summary": "Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. Further, the company provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Comfort, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Additionally, it offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. The company has various agreements with Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, and Schwabe. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy SA.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "state": null,
        "city": "Boulogne-Billancourt",
        "zipcode": "92650",
        "website": "http://www.ipsen.com",
        "full_time_employees": 5703
    },
    "IPN.PA": {
        "short_name": "IPSEN",
        "long_name": "Ipsen S.A.",
        "summary": "Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. Further, the company provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Comfort, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Additionally, it offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. The company has various agreements with Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, and Schwabe. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy SA.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "state": null,
        "city": "Boulogne-Billancourt",
        "zipcode": "92650",
        "website": "http://www.ipsen.com",
        "full_time_employees": 5703
    },
    "IPN.VI": {
        "short_name": "IPSEN",
        "long_name": "Ipsen S.A.",
        "summary": "Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. Further, the company provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Comfort, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Additionally, it offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. The company has various agreements with Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, and Schwabe. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy SA.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "VIE",
        "market": "at_market",
        "country": "France",
        "state": null,
        "city": "Boulogne-Billancourt",
        "zipcode": "92650",
        "website": "http://www.ipsen.com",
        "full_time_employees": 5703
    },
    "IPSEY": {
        "short_name": "IPSEN SA",
        "long_name": "Ipsen S.A.",
        "summary": "Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. Further, the company provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Comfort, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Additionally, it offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. The company has various agreements with Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, and Schwabe. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy SA.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "state": null,
        "city": "Boulogne-Billancourt",
        "zipcode": "92650",
        "website": "http://www.ipsen.com",
        "full_time_employees": 5703
    },
    "MLGML.PA": {
        "short_name": "GOUR MEDICAL",
        "long_name": "Gour Medical SA",
        "summary": "Gour Medical SA engages in the development and commercialization of veterinary drugs. The company develops various medicines and food supplements to enhance the health of mature pets. Its product portfolio includes Gour-153, a pain product; and Gour-419, an atopic dermatitis product. Gour Medical SA was founded in 2014 and is based in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "state": null,
        "city": "Paris",
        "zipcode": "75001",
        "website": "http://www.gour-medical.com",
        "full_time_employees": null
    },
    "VETO.PA": {
        "short_name": "VETOQUINOL",
        "long_name": "Vetoquinol SA",
        "summary": "Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of pain management, anti-infective, cardiology-nephrology, care and hygiene, antiparasiticides, behavior, internal medicine, and reproduction for cats, dogs, cattle, and pigs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "state": null,
        "city": "Lure",
        "zipcode": "70204",
        "website": "http://www.vetoquinol.com",
        "full_time_employees": 2409
    }
}